Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders (2015 - 2026)
Insight Molecular Diagnostics (IMDX) posted Net Income towards Common Stockholders of -$11.2 million for Q1 2026, up 51.03% sequentially from -$23.0 million in Q4 2025, and down 68.52% YoY from -$35.7 million in Q1 2025.
Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported Net Income towards Common Stockholders for 12 years, with the latest figure at -$11.2 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 68.52% year-over-year to -$11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.8 million (up 5.95% YoY) and the FY2025 annual result came in at -$50.2 million, up 17.57% from the prior year.
- Net Income towards Common Stockholders rose to -$11.2 million in Q1 2026 per IMDX's latest filing, from -$23.0 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $9.1 million in Q4 2022 and troughed at -$33.5 million in Q4 2024.
- A 5-year average of -$10.0 million and a median of -$9.6 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders soared 125.32% in 2022, then plunged 190649.09% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at $9.1 million in 2022, then slumped by 246.04% to -$13.3 million in 2023, then slumped by 152.55% to -$33.5 million in 2024, then soared by 31.5% to -$23.0 million in 2025, then surged by 51.03% to -$11.2 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$11.2 million, -$23.0 million, and -$10.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 338.41 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 339.00 Mn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 241.00 Mn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -85.11 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 207.00 Mn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 232.90 Mn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 324.00 Mn |
| 10 | Insight Molecular Diagnostics | 172.42 Mn | 143.49 Mn | 15,000.00 | -11.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.24 Mn |
| Dec 31, 2025 | -22.96 Mn |
| Sep 30, 2025 | -10.85 Mn |
| Jun 30, 2025 | -9.74 Mn |
| Mar 31, 2025 | -6.67 Mn |
| Dec 31, 2024 | -33.51 Mn |
| Sep 30, 2024 | -13.49 Mn |
| Jun 30, 2024 | -4.59 Mn |
| Mar 31, 2024 | -9.34 Mn |
| Dec 31, 2023 | -13.27 Mn |
| Sep 30, 2023 | -6.69 Mn |
| Jun 30, 2023 | -8.64 Mn |
| Mar 31, 2023 | 4,899.00 |
| Dec 31, 2022 | 9.09 Mn |
| Sep 30, 2022 | -9.63 Mn |
| Jun 30, 2022 | -8.37 Mn |
| Mar 31, 2022 | -10.29 Mn |
| Dec 31, 2021 | -35.89 Mn |
| Sep 30, 2021 | -13.80 Mn |
| Jun 30, 2021 | -10.49 Mn |